

Please join: **Amesh Adalja, MD**

For the event: **Contemporary evidence supporting the appropriate role of a treatment option for HABP/VABP**

## Learning objectives:

Review epidemiology of common gram-negative bacteria associated with HABP/VABP

Review clinical data supporting a treatment option for certain patients with HABP/VABP

Discuss the appropriate role of a treatment option for HABP/VABP, including pathogen coverage and recent guidance

## Speaker: **Amesh Adalja, MD**

Amesh Adalja, M.D is a Senior Scholar and Adjunct Assistant Professor at the Center for Health Security at the Bloomberg School of Public Health at Johns Hopkins University. Dr. Adalja attended American University the Caribbean and completed a residency program in Internal Medicine and Emergency Medicine at Allegheny General Hospital. Dr. Adalja completed postgraduate training in Infectious Diseases and Critical Care Medicine at the University of Pittsburgh. Dr. Adalja is board certified in the areas of Internal Medicine, Emergency Medicine, Infectious Diseases, and Critical Care Medicine. Dr. Adalja is a member of several professional societies, including the Society of Critical Care Medicine and is a fellow of the Infectious Diseases Society Of America.



Start time:

**9/16/2025 6:30 PM**

End time:

**9/16/2025 8:00 PM**



**Herbies**

8100 Maryland Avenue

Clayton, MO 63105



**Space is limited.** Please contact the representative listed below before **9/16/2025** to confirm your reservation.



Regards,

**Katherine Milsap**

katherine.milsap@merck.com +1 (314) 6511372

Merck is pleased to sponsor this event, which contains information consistent with FDA guidelines. This event is not an accredited CME program and is not designed to meet any training and/or educational requirements.

Merck Medical Forums are educational meetings and do not include alcoholic beverages.

The speaker for this event is speaking on behalf of Merck.